Sakata Yasuhiko, Nochioka Kotaro, Yasuda Satoshi, Ishida Koichi, Shiroto Takashi, Takahashi Jun, Kasahara Shintaro, Abe Ruri, Yamanaka Shinsuke, Fujihashi Takahide, Hayashi Hideka, Kato Shintaro, Horii Katsunori, Teramoto Kanako, Tomita Tsutomu, Miyata Satoshi, Sugimura Koichiro, Waga Iwao, Nagasaki Masao, Shimokawa Hiroaki
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
Eur J Heart Fail. 2025 Apr 15. doi: 10.1002/ejhf.3654.
The clinical guidelines categorize heart failure (HF) based on left ventricular ejection fraction (LVEF). However, the current LVEF cutoffs, 40% and 50%, may not fully address the underlying characteristics and cardiovascular risk of HF, particularly for HF with higher LVEF. This study aimed to characterize HF with supranormal ejection fraction (HFsnEF) using different LVEF cutoffs (35%, 55%, and 70% for men, and 40%, 60%, and 75% for women).
This study divided 442 patients from the CHART-Omics study into four groups: HF with reduced ejection fraction (HFrEF) (n = 55, 65.5 years), HF with mildly reduced ejection fraction (HFmrEF) (n = 125, 69.3 years), HF with normal ejection fraction (HFnEF) (n = 215, 69.0 years) and HFsnEF (n = 47, 67.1 years). When clinical backgrounds were adjusted and HFnEF served as the reference, HFsnEF carried an increased hazard ratio (HR) for the composite of cardiovascular death and HF hospitalization of 2.71 (95% confidence interval [CI] 1.10-6.66, p = 0.030), while HFrEF had a HR of 3.14 (95% CI 1.36-7.23, p = 0.007). HFsnEF was characterized by an increase in relative left ventricular wall thickness and a decrease in left ventricular dimensions, whereas increased left ventricular mass and dimensions characterized HFrEF. Quantitative analysis of 4670 plasma proteins showed essential differences between HFsnEF and HFrEF, for example, 'protein synthesis' versus 'cell morphology', 'cellular assembly and organization' and 'nucleic acid metabolism' for underlying pathophysiology, and 'energy production' versus 'connective tissue disorders' and 'cell-to-cell signalling and interaction' for prognostication.
Heart failure with supranormal ejection fraction, an unnoticed but emerging entity in HF, carries a similarly increased cardiovascular risk as HFrEF but has unique structural and plasma proteomic characteristics.
临床指南根据左心室射血分数(LVEF)对心力衰竭(HF)进行分类。然而,目前40%和50%的LVEF临界值可能无法完全涵盖HF的潜在特征和心血管风险,特别是对于LVEF较高的HF。本研究旨在使用不同的LVEF临界值(男性为35%、55%和70%,女性为40%、60%和75%)来描述射血分数超常的心力衰竭(HFsnEF)。
本研究将CHART - Omics研究中的442例患者分为四组:射血分数降低的心力衰竭(HFrEF)(n = 55,65.5岁)、射血分数轻度降低的心力衰竭(HFmrEF)(n = 125,69.3岁)、射血分数正常的心力衰竭(HFnEF)(n = 215,69.0岁)和HFsnEF(n = 47,67.1岁)。在调整临床背景并以HFnEF作为对照时,HFsnEF发生心血管死亡和HF住院复合事件的风险比(HR)为2.71(95%置信区间[CI] 1.10 - 6.66,p = 0.030),而HFrEF的HR为3.14(95% CI 1.36 - 7.23,p = 0.007)。HFsnEF的特征是相对左心室壁厚度增加和左心室尺寸减小,而HFrEF的特征是左心室质量和尺寸增加。对4670种血浆蛋白的定量分析显示HFsnEF和HFrEF之间存在本质差异,例如,在潜在病理生理学方面,是“蛋白质合成”与“细胞形态”、“细胞组装和组织”以及“核酸代谢”的差异,在预后方面,是“能量产生”与“结缔组织疾病”以及“细胞间信号传导和相互作用”的差异。
射血分数超常的心力衰竭是HF中一个未被注意但正在出现的实体,其心血管风险增加程度与HFrEF相似,但具有独特的结构和血浆蛋白质组学特征。